ArkBio secures China IND approval for long-acting antiviral AK0406, advancing influenza prophylaxis development
Executive summary: ArkBio received IND approval from Chinese regulators for AK0406 injection, its antiviral drug-Fc conjugate candidate for influenza prophylaxis. The approval allows ArkBio to advance AK0406 into clinical testing in China, representing a step toward a potential long-acting preventive option for influenza.
Who is involved: Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio), Chinese National Medical Products Administration (NMPA).
Likely next: ArkBio will proceed with clinical trial preparation and initiation for AK0406 in China, followed by potential global regulatory engagement.
Shanghai Ark Biopharmaceutical Co., Ltd. (ArkBio) announced on August 12, 2026 that its Investigational New Drug (IND) application for AK0406 injection has been approved by Chinese regulators. AK0406 is the company's first long-acting antiviral drug-Fc conjugate (AFC) candidate designed for influenza prophylaxis. This approval marks a key regulatory milestone enabling progression to clinical trials in China. The development focuses on preventing influenza through extended-duration antiviral protection using Fc fusion technology.
Timeline
- — ArkBio Announces China IND Approval for its Antiviral Drug-Fc Conjugate (AFC) Candidate AK0406 for Influenza Prophylaxis (PR Newswire)
- — Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia (PR Newswire)
- — Ceramedix Awarded Up to $4.5 Million NIAID Contract to Advance Lead GI-ARS Therapeutic Toward IND Submission (PR Newswire)
Analysis — what this means
Likely next events
- ArkBio to initiate Phase I clinical trials for AK0406 in China within 6 months
- Potential disclosure of preclinical efficacy and safety data for AK0406 by Q1 2027
Sectors affected
- Biopharmaceuticals
- Antiviral therapeutics
- Influenza prophylaxis
Regulatory implications
- China NMPA IND approval permits clinical trial initiation for AK0406
- Global development may follow successful China data, requiring alignment with FDA/EMA pathways
Historical parallels
- FDA IND approval for Graviton BioScience's GV101 for Friedreich's ataxia, August 2026
- Ceramedix NIAID contract advance for GI-ARS therapeutic toward IND submission, August 2026
Key entities
Sources
Open the full interactive case file on Beyond →